| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial.
|
JAMA
|
2004
|
23.69
|
|
2
|
Low-fat dietary pattern and risk of cardiovascular disease: the Women's Health Initiative Randomized Controlled Dietary Modification Trial.
|
JAMA
|
2006
|
12.44
|
|
3
|
Calcium plus vitamin D supplementation and the risk of fractures.
|
N Engl J Med
|
2006
|
12.09
|
|
4
|
Estrogen plus progestin and the risk of coronary heart disease.
|
N Engl J Med
|
2003
|
10.06
|
|
5
|
Angiotensin-converting-enzyme inhibition in stable coronary artery disease.
|
N Engl J Med
|
2004
|
9.67
|
|
6
|
Calcium plus vitamin D supplementation and the risk of colorectal cancer.
|
N Engl J Med
|
2006
|
8.73
|
|
7
|
Estrogen therapy and coronary-artery calcification.
|
N Engl J Med
|
2007
|
8.70
|
|
8
|
Menopausal hormone therapy and health outcomes during the intervention and extended poststopping phases of the Women's Health Initiative randomized trials.
|
JAMA
|
2013
|
7.19
|
|
9
|
Low-fat dietary pattern and risk of invasive breast cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial.
|
JAMA
|
2006
|
6.51
|
|
10
|
Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/progestin Replacement Study follow-up (HERS II).
|
JAMA
|
2002
|
4.91
|
|
11
|
Statins for the primary prevention of cardiovascular events in women with elevated high-sensitivity C-reactive protein or dyslipidemia: results from the Justification for the Use of Statins in Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) and meta-analysis of women from primary prevention trials.
|
Circulation
|
2010
|
4.37
|
|
12
|
Effects of hormone replacement therapy and antioxidant vitamin supplements on coronary atherosclerosis in postmenopausal women: a randomized controlled trial.
|
JAMA
|
2002
|
3.88
|
|
13
|
Conjugated equine estrogens and global cognitive function in postmenopausal women: Women's Health Initiative Memory Study.
|
JAMA
|
2004
|
3.85
|
|
14
|
Comparison of self-report, hospital discharge codes, and adjudication of cardiovascular events in the Women's Health Initiative.
|
Am J Epidemiol
|
2004
|
3.53
|
|
15
|
Effect of lowering LDL cholesterol substantially below currently recommended levels in patients with coronary heart disease and diabetes: the Treating to New Targets (TNT) study.
|
Diabetes Care
|
2006
|
3.37
|
|
16
|
The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants.
|
Ann Epidemiol
|
2003
|
3.03
|
|
17
|
Low-fat dietary pattern and risk of colorectal cancer: the Women's Health Initiative Randomized Controlled Dietary Modification Trial.
|
JAMA
|
2006
|
2.97
|
|
18
|
Prognostic value of B-Type natriuretic peptides in patients with stable coronary artery disease: the PEACE Trial.
|
J Am Coll Cardiol
|
2007
|
2.40
|
|
19
|
Depressive symptoms and heart rate variability in postmenopausal women.
|
Arch Intern Med
|
2005
|
2.08
|
|
20
|
Calcium/vitamin D supplementation and coronary artery calcification in the Women's Health Initiative.
|
Menopause
|
2010
|
2.00
|
|
21
|
Statin use, clinical fracture, and bone density in postmenopausal women: results from the Women's Health Initiative Observational Study.
|
Ann Intern Med
|
2003
|
1.81
|
|
22
|
Prognostic significance of the Centers for Disease Control/American Heart Association high-sensitivity C-reactive protein cut points for cardiovascular and other outcomes in patients with stable coronary artery disease.
|
Circulation
|
2007
|
1.76
|
|
23
|
Can biomarkers identify women at increased stroke risk? The Women's Health Initiative Hormone Trials.
|
PLoS Clin Trials
|
2007
|
1.54
|
|
24
|
Coronary artery calcification in black women and white women.
|
Am Heart J
|
2003
|
1.52
|
|
25
|
Validation of self-report of rheumatoid arthritis and systemic lupus erythematosus: The Women's Health Initiative.
|
J Rheumatol
|
2008
|
1.47
|
|
26
|
Inflammatory, lipid, thrombotic, and genetic markers of coronary heart disease risk in the women's health initiative trials of hormone therapy.
|
Arch Intern Med
|
2008
|
1.34
|
|
27
|
Influence of albuminuria on cardiovascular risk in patients with stable coronary artery disease.
|
Circulation
|
2007
|
1.24
|
|
28
|
Application of serum proteomics to the Women's Health Initiative conjugated equine estrogens trial reveals a multitude of effects relevant to clinical findings.
|
Genome Med
|
2009
|
1.21
|
|
29
|
Prognostic utility of lipoprotein-associated phospholipase A2 for cardiovascular outcomes in patients with stable coronary artery disease.
|
Arterioscler Thromb Vasc Biol
|
2007
|
1.20
|
|
30
|
Renal insufficiency and the risk of lower extremity peripheral arterial disease: results from the Heart and Estrogen/Progestin Replacement Study (HERS).
|
J Am Soc Nephrol
|
2004
|
1.20
|
|
31
|
Efficacy and safety of rosuvastatin therapy for children with familial hypercholesterolemia.
|
J Am Coll Cardiol
|
2010
|
1.19
|
|
32
|
Effects of rosuvastatin and atorvastatin on LDL and HDL particle concentrations in patients with metabolic syndrome: a randomized, double-blind, controlled study.
|
Diabetes Care
|
2009
|
1.14
|
|
33
|
Normal standards for QT and QT subintervals derived from a large ethnically diverse population of women aged 50 to 79 years (the Women's Health Initiative [WHI]).
|
Am J Cardiol
|
2006
|
1.11
|
|
34
|
Lipoprotein-associated phospholipase A2, hormone use, and the risk of ischemic stroke in postmenopausal women.
|
Hypertension
|
2008
|
1.09
|
|
35
|
Postmenopausal estrogen and progestin effects on the serum proteome.
|
Genome Med
|
2009
|
1.07
|
|
36
|
Predictors of heart failure in patients with stable coronary artery disease: a PEACE study.
|
Circ Heart Fail
|
2009
|
1.04
|
|
37
|
Oophorectomy, hormone therapy, and subclinical coronary artery disease in women with hysterectomy: the Women's Health Initiative coronary artery calcium study.
|
Menopause
|
2008
|
0.95
|
|
38
|
Novel proteins associated with risk for coronary heart disease or stroke among postmenopausal women identified by in-depth plasma proteome profiling.
|
Genome Med
|
2010
|
0.92
|
|
39
|
Cost effectiveness of rosuvastatin in patients at risk of cardiovascular disease based on findings from the JUPITER trial.
|
J Med Econ
|
2010
|
0.86
|
|
40
|
Estrogen receptor polymorphisms and the vascular effects of hormone therapy.
|
Arterioscler Thromb Vasc Biol
|
2010
|
0.85
|
|
41
|
Relationships of coronary heart disease with 27-hydroxycholesterol, low-density lipoprotein cholesterol, and menopausal hormone therapy.
|
Circulation
|
2012
|
0.84
|
|
42
|
Pharmacokinetic interaction study of ticagrelor and cyclosporine in healthy volunteers.
|
Clin Drug Investig
|
2014
|
0.83
|
|
43
|
Postmenopausal hormone therapy is associated with atherosclerosis progression in women with abnormal glucose tolerance.
|
Circulation
|
2004
|
0.83
|
|
44
|
Cigarette smoking and risk of benign proliferative epithelial disorders of the breast in the Women's Health Initiative.
|
Cancer Causes Control
|
2007
|
0.82
|
|
45
|
Comparing the effectiveness of rosuvastatin and atorvastatin in preventing cardiovascular outcomes: estimates using the Archimedes model.
|
J Med Econ
|
2012
|
0.81
|
|
46
|
Association between different measures of blood pressure and coronary artery calcium in postmenopausal women.
|
Hypertension
|
2008
|
0.79
|
|
47
|
Panic attacks, daily life ischemia, and chest pain in postmenopausal women.
|
Psychosom Med
|
2006
|
0.79
|
|
48
|
Women's Ischemic Syndrome Evaluation: current status and future research directions: report of the National Heart, Lung and Blood Institute workshop: October 2-4, 2002 : Section 4: lessons from hormone replacement trials.
|
Circulation
|
2004
|
0.78
|
|
49
|
Calcium and heart attacks. No evidence for increased risk.
|
BMJ
|
2010
|
0.78
|
|
50
|
An open-label, randomized bioavailability study with alternative methods of administration of crushed ticagrelor tablets in healthy volunteers.
|
Int J Clin Pharmacol Ther
|
2015
|
0.76
|
|
51
|
Remnant-like lipoproteins, hormone therapy, and angiographic and clinical outcomes: the Women's Angiographic Vitamin & Estrogen Trial.
|
Am Heart J
|
2004
|
0.76
|
|
52
|
Prevalence, clinical significance, and management of peripheral arterial disease in women: is there a role for postmenopausal hormone therapy?
|
Vasc Health Risk Manag
|
2005
|
0.75
|
|
53
|
Coronary heart disease prevention in menopausal women.
|
Expert Opin Pharmacother
|
2005
|
0.75
|